

## Reviva to Participate in the 2025 BIO CEO & Investor Conference

CUPERTINO, Calif., Jan. 30, 2025 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY.

### 2025 BIO CEO & Investor Conference

Panel Title: *Tackling Mental Health through New Targets and Endpoints Progress*

Date: Tuesday, February 11, 2025

Time: 1:00 p.m. ET

Location: New York, NY

To register for the conference and schedule a one-on-one meeting with Reviva management, please use the link [HERE](#).

### About Reviva

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

### Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD

[www.revivapharma.com](http://www.revivapharma.com)

### Investor Relations Contact:

LifeSci Advisors, LLC

Bruce Mackle

[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)

